MAPT and Alzheimer disease: An et al. (2017) found that Aβ oligomerization was significantly higher in AD patients than in normal people. Plus, the high correlations between Aβ oligomerization levels and other AD biomarkers, such as phosphorylated tau protein (pTau), amyloid positron emission tomography (PET) imaging, CSF biomarkers for Aβ42, total tau, and brain magnetic resonance imaging (MRI) were confirmed in many studies (Choi et al., 2021; Cheng et al., 2022).